GET DAILY SIGNALSCelcuity (CELC) Reports Q3 Net Loss of $73.3 Million as Commercial Build-Out Accelerates
Key Takeaways
- Celcuity reported a third quarter 2026 net loss of $73.3 million, or $1.33 per share, compared with a net loss of $43.8 million, or $0.92 per share, in the prior-year period.
- The reported loss per share was narrower than the consensus estimate of roughly $1.45, even as total operating expenses rose to $77.3 million from $42.8 million a year earlier.
- No product revenue was recognized in the quarter because REVTORPYK shipments began on September 30, 2026, with revenue booked only upon delivery to treatment locations.
- Selling, general, and administrative (SG&A) expenses more than tripled to $39.8 million as the company built out its commercial infrastructure for REVTORPYK.
- Cash, cash equivalents, and short-term investments totaled $642.7 million at quarter-end, which management expects to fund operations through 2029.
Earnings Context and Why It Matters
CELC has moved from a clinical-stage developer into a commercial-stage biotechnology company, and this quarter captures the pivotal moment of that shift. REVTORPYK (gedatolisib), the company's first U.S. Food and Drug Administration (FDA)-approved product, became commercially available on September 30, 2026, for adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer without a PIK3CA mutation. Because the launch landed at the very end of the quarter, the third quarter still reflects pre-revenue spending rather than product sales. I’m watching this closely to understand how quickly the company's substantial commercial investment translates into revenue and whether its cash position supports the growth plan. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
CELC reported a third quarter 2026 net loss of $73.3 million, or $1.33 per share, versus a net loss of $43.8 million, or $0.92 per share, in the year-ago period. Non-GAAP adjusted net loss, which excludes stock-based compensation and certain non-cash items, was $66.8 million, or $1.21 per share, compared with $37.2 million, or $0.78 per share, a year earlier. The reported loss was narrower than the consensus estimate of approximately $1.45 per share.
Total operating expenses climbed to $77.3 million from $42.8 million. Research and development (R&D) expenses rose to $37.5 million from $30.4 million, while SG&A expenses surged to $39.8 million from $12.4 million, with about $25.3 million of that increase tied to commercial headcount and launch activities. The company recorded no product revenue in the quarter, and net cash used in operating activities was $66.2 million. CELC also made a $50.0 million milestone payment to Pfizer following FDA approval of REVTORPYK.
Market Reaction and Investor Sentiment
Heading into the report, sentiment centered on the commercial launch of REVTORPYK and the pace of spending required to support it. Because the company had flagged that shipments began only at quarter-end, investors largely anticipated a quarter with no product revenue. The narrower-than-expected loss per share and the disclosure that 91% of U.S. commercial and Medicare lives are covered by health plans for REVTORPYK, including 78% of the top 36 strategic accounts, provided a clearer picture of early commercial reach. Attention now shifts to the first revenue flash report, expected in mid-January, which will offer the first tangible read on launch demand.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the fourth quarter 2026 sales update, which CELC expects to provide in mid-January. That report should deliver the first meaningful data on vials shipped, gross-to-net sales, and real-world uptake of REVTORPYK. Management has indicated that revenue will be recognized upon delivery, so the fourth quarter will begin to reflect actual product sales rather than pre-launch preparation.
Investors should also track the company's supplemental New Drug Application (NDA) filed with the FDA in the third quarter to expand the REVTORPYK label to PIK3CA-mutant patients. Updated Phase 3 VIKTORIA-1 data presented at the European Society for Medical Oncology (ESMO) meeting showed gedatolisib-based regimens improving median progression-free survival (PFS) versus alpelisib plus fulvestrant, and further updates are expected at the San Antonio Breast Cancer Symposium.
Finally, cost discipline remains a key watch item. With SG&A spending elevated by the commercial build-out and a cash position of $642.7 million expected to fund operations through 2029, the market will be watching whether early revenue growth justifies the higher expense base. Additional data from the VIKTORIA-2 first-line breast cancer program and the prostate cancer study represent longer-term drivers that could shape the company's trajectory beyond the initial launch.
Using Tickeron AI Tools in My Research Process
From what I see, Tickeron’s AI Screener has become a useful part of my workflow when evaluating names in the biotech space. It helps filter for patterns, fundamentals, and performance metrics across thousands of stocks, which can surface relevant comparisons quickly. I find it especially handy for monitoring how a company like CELC stacks up against peers during periods of transition like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CELC turns negative, indicating new downward trend
CELC saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 88 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 62 cases where CELC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELC's RSI Oscillator exited the oversold zone, 19 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for CELC just turned positive on October 22, 2026. Looking at past instances where CELC's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CELC's P/B Ratio (-245.176) is very low in comparison to the industry average of (2.788). P/E Ratio (-14.893) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. CELC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company develops novel diagnostic tests
Industry Biotechnology
Advertisement